Ahir Bhavesh K, Elias Nasya M, Lakka Sajani S
Section of Hematology and Oncology, Department of Medicine, University of Illinois College of Medicine at Chicago, Chicago, IL, USA.
Genes Cancer. 2017 Jan;8(1-2):453-471. doi: 10.18632/genesandcancer.130.
Medulloblastoma is the most common malignant brain tumor in children. SPARC (secreted protein acidic and rich in cysteine), a multicellular non-structural glycoprotein is known to be involved in multiple processes in various cancers. Previously, we reported that SPARC expression significantly impairs medulloblastoma tumor growth and and also alters chemo sensitivity. MicroRNAs are a class of post-transcriptional gene regulators with critical functions in tumor progression. In addition, microRNA (miRNA) expression changes are also involved in chemo-resistance. Herein, we assessed microRNA (miRNA) profiling to identify the functional network and biological pathways altered in SPARC-overexpressed medulloblastoma cells. A total of 27 differentially expressed miRNAs were identified between the control and SPARC-overexpressed samples. Potential messenger RNA (mRNA) targets of the differentially expressed miRNA were identified using Ingenuity Pathway Analysis (IPA). Network-based functional analyses were performed on the available human protein interaction and miRNA-gene association data to highlight versatile miRNAs among the significantly deregulated miRNAs using the IPA, and the biological pathway analysis using the PANTHER web-based tool. We have identified six miRNAs (miR-125b1*, miR-146a-5p, miR-181a-5p, miR-204-5p, miR-219-5p and miR-509-3p) that are associated with SPARC sensitivity by comparison of miRNA expression patterns from the SPARC treated cells with the control cells. Furthermore, pathway enrichment analysis outline that these six microRNAs mainly belong to biological processes related to cancer related signaling pathways. Collectively, these studies have the potential to indicate novel biomarkers for treatment response and can also be applied to develop novel therapeutic treatment for medulloblastoma.
髓母细胞瘤是儿童中最常见的恶性脑肿瘤。SPARC(富含半胱氨酸的酸性分泌蛋白)是一种多细胞非结构糖蛋白,已知其参与多种癌症的多个过程。此前,我们报道SPARC表达显著损害髓母细胞瘤的肿瘤生长,并且还改变化疗敏感性。微小RNA是一类在肿瘤进展中具有关键功能的转录后基因调节因子。此外,微小RNA(miRNA)表达变化也与化疗耐药性有关。在此,我们评估了微小RNA(miRNA)谱,以识别在SPARC过表达的髓母细胞瘤细胞中改变的功能网络和生物学途径。在对照样品和SPARC过表达样品之间共鉴定出27种差异表达的miRNA。使用 Ingenuity Pathway Analysis(IPA)鉴定差异表达miRNA的潜在信使RNA(mRNA)靶标。基于网络的功能分析是利用IPA对可用的人类蛋白质相互作用和miRNA-基因关联数据进行的,目的是在显著失调的miRNA中突出通用的miRNA,并使用基于网络的PANTHER工具进行生物学途径分析。通过比较SPARC处理细胞与对照细胞的miRNA表达模式,我们鉴定出六种与SPARC敏感性相关的miRNA(miR-125b1*、miR-146a-5p、miR-181a-5p、miR-204-5p、miR-219-5p和miR-509-3p)。此外,途径富集分析表明,这六种微小RNA主要属于与癌症相关信号通路相关的生物学过程。总的来说,这些研究有可能为治疗反应指明新的生物标志物,也可用于开发针对髓母细胞瘤的新型治疗方法。